Compare Humana Inc (HUM) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Humana Inc trades at $374.25 (market cap $46.31B), while Marsh & McLennan Companies, Inc. trades at $191.32 (market cap $91.05B). The key difference: Marsh & McLennan Companies, Inc. is the larger of the two by market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.08%). Which is the better fit depends on your goals.
| HUM | MRSH | |
|---|---|---|
Market Cap | $46.31B | $91.05B |
Sector | Health | Financials |
52-Week High | $409.42 | $211.21 |
52-Week Low | $163.67 | $157.32 |
Enterprise Value | $53.67B | $111.73B |
Dividend Yield | 0.92% | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
Marsh & McLennan (MRSH) trades at $191.65, down 0.85% on the day, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.96 exceeding expectations. Revenue growth remains solid at 6% in Q2 2026, while the company maintains healthy profitability with a 14.24% net income margin. Recent acquisitions and AI investments highlight strategic growth initiatives.
The outlook for MRSH is positive, supported by earnings momentum and a consensus price target of $202.89 offering potential upside. However, margin pressure from rising expenses and soft P&C pricing present near-term risks. Institutional activity shows mixed sentiment, with some firms increasing stakes while others reduce holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
